Video Gallery

Immunovia’s pancreatic cancer awareness campaign between August 12 to September 30, 2019 in Times Square, New York City, highlighting the importance of early detection.

WCVB Channel 5 News covered on the 2nd of May 2019, 5 pm EST Immunovia’s IMMray™ PanCan-d for early detection of pancreatic cancer: “Promising results reported for early detection blood test targeting pancreatic cancer”.

&lt;span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”&gt;&lt;/span&gt;
IMMray™ technology:
IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma.

IMMray™ technology – Short Version:
IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma.